



THE FAME STUDY
TWO-YEAR RESULTS

WE ASPIRE TO HAVE FRACTIONAL FLOW RESERVE (FFR) MEASUREMENT BECOME THE STANDARD OF CARE IN CATH LABS AROUND THE WORLD.

Radi Medical Systems, now a part of St. Jude Medical, Inc., pioneered the development of FFR, which resulted in the market-leading device PressureWire™ and put us at the forefront of FFR Technology. It is our commitment to build on this foundation and develop solutions that reduce risk and improve patient outcomes.

St. Jude Medical's PressureWire™ Certus was the exclusive FFR measurement system used in the FAME¹ (Fractional flow reserve vs. Angiography in Multivessel Evaluation) Clinical Study. The one-year results, published in *The New England Journal of Medicine* in January 2009, validated PressureWire's clinical benefits by establishing that, compared to angiography alone, FFR measurement significantly reduces major adverse coronary events, is cost-saving and does not increase procedure time.

FAME Study Methods

- Randomized, prospective study – angiography only or angiography plus FFR
- 20 centers in Europe and U.S.
- 1,005 PCI patients undergoing DES stenting for multivessel disease

PressureWire™

The PressureWire FFR measurement systems provide reliable and complete FFR measurements for improved diagnostic accuracy compared to image-based techniques such as angiography or IVUS.

PressureWire is currently available in a stand-alone configuration or integrated with selected hemodynamic recording systems.



**PressureWire Aeris
Wireless FFR Measurement System**



**PressureWire Certus
FFR Measurement System**

FAME STUDY TWO-YEAR RESULTS

The FAME two-year results, presented at TCT 2009, affirm the advantages of using FFR to guide multivessel intervention. FFR-guided PCI significantly improves patient outcomes and results in reduced procedural and healthcare costs, without prolonging the cath lab procedure, compared to angiography alone.

Outcomes


- reduced mortality and myocardial infarction at two years by 34%
- reduced MI at two years by 37%
- cost-saving and does not prolong procedure time
- decreased amount of contrast agent used

Improved Outcomes at Lower Costs



Bootstrap simulation indicated that the FFR-guided strategy was cost-saving in 99.8% and cost-effective in all 1,000 scenarios.

Two-year Survival Free of Death/MI



Procedural Characteristics

| | ANGIO-Group N=496 | FFR-Group N=509 | P-Value |
|---------------------------------------|----------------------|--------------------|---------|
| DES per Patient, No. | 2.7 ± 1.2 | 1.9 ± 1.3 | < 0.001 |
| Procedure Time, Min. | 70 ± 44 | 71 ± 43 | 0.51 |
| Contrast Agent Used, ML | 302 ± 127 | 272 ± 133 | < 0.001 |
| Materials Used at Procedure, Mean USD | 6007 ± 2819 | 5332 ± 3261 | < 0.001 |
| Length of Hospital Stay, Days | 3.7 ± 3.5 | 3.4 ± 3.3 | 0.05 |

One-year Results

| | ANGIO-Group N=496 | FFR-Group N=509 |
|--|----------------------|--------------------|
| Incremental Health Costs, USD ² | 14357 | 12291 |

Two-year Results, No. (%)

| | ANGIO-Group N=496 | FFR-Group N=509 | P-Value |
|--------------------------------------|----------------------|--------------------|---------|
| Death, MI and Repeat Vascularization | 110 (22.2) | 90 (17.7) | 0.07 |
| Death or Myocardial Infarction | 63 (12.7) | 43 (8.4) | 0.03 |
| Death | 19 (3.8) | 13 (2.6) | 0.25 |
| Myocardial Infarction | 48 (9.7) | 31 (6.1) | 0.03 |
| Freedom from Angina | (75.8) | (79.9) | 0.14 |
| Follow-up | (92.7) | (94.5) | 0.34 |

St. Jude Medical is focused on reducing risk by continuously finding ways to put more control into the hands of those who save and enhance lives.

1. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med.* 2009;360(3):213-24
2. ESC (European Society of Cardiology) 2009 Clinical Trials Update III presentation slides (PDF) and Webcast available at: www.escardio.org
3. TCT (Transcatheter Cardiovascular Therapeutics) 2009, Late Breaking Clinical Trials

ATRIAL FIBRILLATION CARDIAC RHYTHM MANAGEMENT CARDIOVASCULAR NEUROMODULATION

Global Headquarters

One St. Jude Medical Drive
St. Paul, Minnesota 55117
USA
+1 651 756 2000
+1 651 756 3301 Fax

Cardiovascular Division

177 East County Road B
St. Paul, Minnesota 55117
USA
+1 651 756 4470
+1 651 756 4466 Fax

Radi Medical Systems AB

Box 6350
SE-751 35 Uppsala
Sweden
+46 18 161000
+46 18 161099 Fax

U.S. Division

807 Las Cimas Parkway
Suite 400
Austin, Texas 78746
USA
+1 512 732 7400
+1 512 732 2418 Fax

**St. Jude Medical Coordination
Center BVBA**

The Corporate Village
Da Vincilaan 11 Box F1
1935 Zaventem
Belgium
+32 2 774 68 11
+32 2 772 83 84 Fax

St. Jude Medical Japan Co., Ltd.

3-1-30, Minami-Aoyama
Minato-ku
Tokyo 107 0062
Japan
+81 3 3423 6450
+81 3 3402 5586 Fax

St. Jude Medical (Hong Kong) Ltd.

Suite 1608, 16/F Exchange Tower
33 Wang Chiu Road
Kowloon Bay, Kowloon
Hong Kong SAR
+852 2996 7688
+852 2956 0622 Fax

St. Jude Medical Brasil Ltda.

Rua Frei Caneca, 1380
7º ao 9º andares
01307-002 - São Paulo (SP)
Brazil
+55 11 5080 5400
+55 11 5080 5423 Fax

SJMprofessional.com



ST. JUDE MEDICAL™

MORE CONTROL. LESS RISK.

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

PressureWire is designed, developed and manufactured by Radi Medical Systems AB. Patent Pending. Unless otherwise noted, ™ indicates a registered or unregistered trademark or service mark owned by, or licensed to, St. Jude Medical, Inc. or one of its subsidiaries. PressureWire, RADI, ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are registered and unregistered trademarks and service marks of St. Jude Medical, Inc. and its related companies.
©2009 St. Jude Medical, Inc. All rights reserved.

Item 100026054

CE
0413